Tvardi Therapeutics, Inc. (TVRD)
1.80
-0.02
(-1.10%)
USD |
NASDAQ |
Aug 31, 16:00
1.83
+0.03
(+1.67%)
After-Hours: 04:20
Tvardi Therapeutics Net Income (Quarterly) : -6.457M for June 30, 2026
Net Income (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Net Income (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -6.457M |
| March 31, 2026 | -6.804M |
| December 31, 2025 | -7.275M |
| September 30, 2025 | -5.527M |
| June 30, 2025 | 4.167M |
| March 31, 2025 | -9.579M |
| December 31, 2024 | -12.71M |
| September 30, 2024 | -5.513M |
| June 30, 2024 | -6.975M |
| March 31, 2024 | -30.70M |
| December 31, 2023 | -32.34M |
| September 30, 2023 | -28.03M |
| June 30, 2023 | -31.48M |
| March 31, 2023 | -26.66M |
| December 31, 2022 | -30.34M |
| September 30, 2022 | -23.18M |
| June 30, 2022 | -4.206M |
| March 31, 2022 | -27.75M |
| December 31, 2021 | -33.38M |
| September 30, 2021 | -1.013M |
| June 30, 2021 | -30.74M |
| March 31, 2021 | -23.30M |
| December 31, 2020 | 78.91M |
| September 30, 2020 | -16.51M |
| June 30, 2020 | -25.07M |
| Date | Value |
|---|---|
| March 31, 2020 | -28.92M |
| December 31, 2019 | -28.61M |
| September 30, 2019 | -32.84M |
| June 30, 2019 | -22.96M |
| March 31, 2019 | -21.96M |
| December 31, 2018 | -20.65M |
| September 30, 2018 | -19.40M |
| June 30, 2018 | -17.19M |
| March 31, 2018 | -16.77M |
| December 31, 2017 | -14.18M |
| September 30, 2017 | -12.44M |
| June 30, 2017 | -9.30M |
| March 31, 2017 | -22.20M |
| December 31, 2016 | -21.97M |
| September 30, 2016 | -11.54M |
| June 30, 2016 | -13.08M |
| March 31, 2016 | -10.69M |
| December 31, 2015 | -9.53M |
| September 30, 2015 | -4.787M |
| June 30, 2015 | -5.684M |
| March 31, 2015 | -4.689M |
| December 31, 2014 | -4.172M |
| September 30, 2014 | -6.545M |
| June 30, 2014 | -3.645M |
| March 31, 2014 | -3.383M |
Net Income Definition
Represents net income for the period and date(s) requested in local currency by default.
Net Income (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Net Income (Quarterly) Benchmarks
| Eli Lilly & Co. | 7.095B |
| Crinetics Pharmaceuticals, Inc. | -120.86M |
| Liquidia Corp. | 74.72M |
| ANI Pharmaceuticals, Inc. | 23.00M |
| Corcept Therapeutics, Inc. | 42.14M |
Net Income (Quarterly) Related Metrics
| Total Expenses (Quarterly) | 6.457M |
| EPS Diluted (Quarterly) | -0.6883 |
| Enterprise Value | 1.266M |
| Earnings Yield | -154.4% |
| Normalized Earnings Yield | -154.36 |